Company Description
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.
The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.
The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Steven Kelly |
Contact Details
Address: 3675 Market Street, Suite 200 Philadelphia, Pennsylvania 19104 United States | |
| Phone | (267) 491-6422 |
| Website | carismatx.com |
Stock Details
| Ticker Symbol | CARM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001485003 |
| ISIN Number | US14216R1014 |
| Employer ID | 26-2025616 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven Kelly | President, Chief Executive Officer and Director |
| Michael Klichinsky Ph.D., Pharm.D., PharmD | Co-Founder and Chief Scientific Officer |
| Richard S. Morris CPA | Chief Financial Officer, Chief Compliance Officer, Treasurer, Prin. Financial Off. and Prin. Acc. Off. |
| Saar Gill M.D., Ph.D. | Co-Founder |
| Dr. Daniel J. Cushing FCP, Ph.D. | Chief Technology and Development Officer |
| Eric H. Siegel J.D., MBA | General Counsel and Corporate Secretary |
| Terry Shields | Senior Vice President of Human Resources |
| Tom Wilton | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |